1. Title of Derivative Security (Instr. 4) |
2. Date Exercisable and Expiration Date (Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) |
4. Conversion or Exercise Price of Derivative Security |
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) |
6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Non-Qualified Stock Option
(1)
(7)
|
11/21/2008 |
10/16/2013 |
Common Stock
|
6,523
|
$
26.7
|
D
|
Â
|
Non-Qualified Stock Option
(2)
|
11/21/2008 |
10/21/2014 |
Common Stock
|
8,002
|
$
21.74
|
D
|
Â
|
Non-Qualified Stock Option
(3)
|
11/21/2008 |
10/20/2015 |
Common Stock
|
7,828
|
$
26.74
|
D
|
Â
|
Non-Qualified Stock Option
(4)
|
11/21/2008 |
10/19/2016 |
Common Stock
|
7,828
|
$
38.8
|
D
|
Â
|
Non-Qualified Stock Option
(5)
|
11/21/2008 |
10/18/2017 |
Common Stock
|
7,828
|
$
41.38
|
D
|
Â
|
Deferred Stock Unit
(6)
|
11/21/2008 |
10/18/2018 |
Common Stock
|
15,930
|
$
0
|
D
|
Â
|
* |
If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** |
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) |
NQSO grant # 00019803. Shares converted to LIFE as a result of the Applied Biosystems merger with Invitrogen Corporation (name subsequently changed to Life Technologies). |
(2) |
NQSO grant # 00022271. Shares converted to LIFE as a result of the Applied Biosystems merger with Invitrogen Corporation (name subsequently changed to Life Technologies). |
(3) |
NQSO grant # 00014428. Shares converted to LIFE as a result of the Applied Biosystems merger with Invitrogen Corporation (name subsequently changed to Life Technologies). |
(4) |
NQSO grant # 0001540. Shares converted to LIFE as a result of the Applied Biosystems merger with Invitrogen Corporation (name subsequently changed to Life Technologies). |
(5) |
NQSO grant # 19737. Shares converted to LIFE as a result of the Applied Biosystems merger with Invitrogen Corporation (name subsequently changed to Life Technologies). |
(6) |
Granted in lieu of director compensation or due to deferral of receipt of vested director grants. |
(7) |
The individual may hold additional shares acquired as a result of the conversion from Applied Biosystems stock to Life Technologies stock. Administration of the conversion is not complete. If it is determined that the individual owns shares, a Form 4A will be filed. |